Longitudinal Trajectories of Memory Performance in Patients with Early-Stage Breast Cancer

Table 2

Cancer-related demographics and treatment at baseline.

	Chemotherapy+hormone therapy group	Hormone therapy group	Chemotherapy group	Control group
Menopausal status (percentage of group)
Premenopausal	15 (45%)	14 (64%)	10 (71%)	--
Postmenopausal	18 (55%)	8 (36%)	4 (29%)	--
Serum estradiol; (Median (range))	15 (2-274)	19 (2-132)	14 (2-286)	14 (2-130)
Expression of ER and/or PR
Positive	33	22	0	--
Negative	0	0	14	--
HER2; (percentage of group)
Positive	4 (12%)	0 (0%)	3 (21%)	--
Negative	29 (88%)	21 (95%)	11 (79%)	--
Treatment; (percentage of group)
Chemotherapy
Anthracycline+taxane	19 (58%)	--	9 (64%)	--
Paclitaxel±cyclophosphamide	12 (36%)	--	3 (21%)	--
Other	2 (6%)	--	2 (14%)	--
Hormone therapy
Aromatase inhibitor	18 (54%)	15 (68%)	--	--
Tamoxifen	14 (42%)	3 (13%)	--	--
Aromatase inhibitor+tamoxifen	1 (3%)	4 (18%)	--	--

Cancer treatment-related demographics at baseline. ER: estrogen receptor; PR: progesterone receptor; : number of subjects; df: degrees of freedom. Chemotherapy regimens consisted of anthracycline+taxane (doxorubicin/cyclophosphamide followed by paclitaxel±trastuzumab, paclitaxel/carboplatin followed by doxorubicin/cyclophosphamide±trastuzumab, paclitaxel/neratinib followed by doxorubicin/cyclophosphamide±trastuzumab, or paclitaxel followed by doxorubicin/cyclophosphamide), cyclophosphamide+paclitaxel (paclitaxel/carboplatin±trastuzumab or paclitaxel/trastuzumab), or other (gemcitabine/carboplatin followed by paclitaxel/carboplatin). Hormone therapy regimens consisted of aromatase inhibition (anastrozole, letrozole, or exemestane) or tamoxifen or both. One participant was missing HER2 data.